Aducanumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Identifiers | |
| CAS Number | 1384260-65-4 |
| ATC code | none |
| ChemSpider | none |
| Chemical data | |
| Molar mass | 145.9 kg/mol |
Aducanumab is the given USAN and INN name for a biopharmaceutical, the human monoclonal antibody and drug candidate BIIB037 designed for treatment of Alzheimer's disease (AD).[1] It is being developed by Biogen Idec, which licensed the drug candidate from Neurimmune, its discoverer.[2] The antibody targets aggregated forms of beta amyloid.[3] Interim results from the second Phase 1 study of the drug were reported at the 12th International Conference on Alzheimer’s and Parkinsons’s Diseases and Related Neurological Disorders (AD/PD 2015), in Nice, France, in March 2015.[1][4]
References
- 1 2 Cynthia Fox for Drug Discovery and Development. April 28, 2015 The Story of Biogen's Alzheimer's Drug, Aducanumab
- ↑ Rebecca Zacks for Xconomy. November 20th, 2007 Biogen Inks $380 Million Deal With Swiss Company
- ↑ Toyn, Jeremy (2015). "What lessons can be learned from failed Alzheimer's disease trials?". Expert Rev. Clin. Pharmacol 8 (3): 267–269. doi:10.1586/17512433.2015.1034690. PMID 25860157.
- ↑ Matthew Herper for Forbes. March 20, 2015 Biogen Drug Could Inspire New Hope For Alzheimer's Treatments
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Friday, April 15, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.